Key Highlights

  • Little Green Pharma (ASX:LGP) shares were up 6.56% at $0.065 during the trading session on 23 October 2026, as at 12:04 pm.
  • In its quarterly report dated 31 July 2026, the company reported cash of $20.6 million at 30 June 2026 and net operating cash flow of $1.8 million.
  • The merger with Cannatrek Ltd completed on 1 June 2026, with $3 million of cost synergies targeted.

Little Green Pharma Ltd (ASX:LGP) shares were up 6.56% at $0.065 during the trading session on 23 October 2026, as at 12:04 pm, while the S&P/ASX 200 stood at 8,762.60, down 0.35% (30.60 points) at the same time. Little Green Pharma is a medicinal cannabis company that merged with Cannatrek Ltd on 1 June 2026, and its most recent update was a quarterly activities report and Appendix 4C dated 31 July 2026 covering the quarter ended 30 June 2026.

Merger With Cannatrek and Synergy Targets

In its quarterly activities report dated 31 July 2026, Little Green Pharma stated that its merger with Cannatrek Ltd was implemented on 1 June 2026, forming the LGP Cannatrek Group, which it described as one of the world's largest pure-play medicinal cannabis businesses. Cost synergies of $3 million have been identified and targeted across manufacturing, cultivation, procurement and corporate functions.

The company reported seven core integration workstreams. It also stated that Cannatrek's domestic GMP manufacturing facility and LGP's GMP Danish facility are key complementary assets.

June Quarter Cash Flow and Funding Position

The 31 July 2026 report showed net cash from operating activities of $1.8 million for the quarter, with receipts from customers of $22.9 million. Payments included $7.8 million for manufacturing and operating costs and $5.6 million for staff costs. Cash and cash equivalents were $20.6 million at 30 June 2026, with $9.2 million in unused financing facilities.

The company cautioned that the Appendix 4C reflects the merger accounting treatment, with cash flows for the former Cannatrek group covering the full quarter and those for the former LGP group covering June 2026 only. For that reason it did not report revenue or prior-quarter comparatives, and said later reports will carry full combined cash flows.

Sales Mix and European Investment

In the same report, the company said its sales mix for the quarter was 84% Australia and 16% Europe, including the UK. By product category, flower represented 79% and oils 13%. Brand contributions were about 60% from Cannatrek and about 40% from LGP, with 75% of sales derived from the core Cannatrek and LGP brands, excluding white-label sales in Europe.

The company also stated that it initiated the first stage of capital investment in its UK and German growth initiatives, including expansion of its Denmark facility. UK market entry and German expansion are described as underway, with partnerships in development.

About the Company and Business Overview

Little Green Pharma Ltd is listed on the ASX under the code LGP, and following the merger operates as the LGP Cannatrek Group. The company describes the group as having vertically integrated operations across Europe and Australia.

It operates GMP cultivation and manufacturing facilities in Denmark and Australia, including what it describes as the largest facility in Europe and one of the largest AU-GMP certified manufacturing facilities in Australia. Its cannabis-based medicines are distributed in Australia and over 11 export markets through wholesalers, pharmacies, clinics and general practitioners, and revenue is generated from product sales and domestic distribution businesses.

Related Sector Context

Medicinal cannabis producers operate in a heavily regulated part of the healthcare sector, where cultivation, manufacturing, import, export and prescribing are each subject to licensing and oversight that differs by jurisdiction.

On 23 October 2026, at 12:04 pm, the S&P/ASX 200 was at 8,762.60, down 0.35%, while Little Green Pharma shares were higher at $0.065. Moves in shares at this price level can differ from the benchmark index.

Risks to Weigh In

The company referred to a regulatory investigation by the Therapeutic Goods Administration. It stated that it anticipates the penalty to be material, though expected to remain within the limits of the CV Shares conversion mechanism. The size and timing of any penalty are therefore a stated uncertainty.

Other uncertainties include the integration of two businesses across seven workstreams, delivery of the $3 million synergy objective, and the capital investment in the UK, Germany and Denmark. Because the reported cash flows combine different periods for each former group, the quarter is not a guide to a full quarter of combined trading.

Catalysts on Watch

The company stated that its September quarterly report and Appendix 4C will contain the combined cash flows of both entities, and that future reports will include unaudited revenue reporting for the LGP Cannatrek Group.

Other items on the horizon include progress against the synergy program, the Denmark facility optimisation initiatives intended to improve yield, efficiency and product quality, and further steps in the UK and German market entry.

Where Things Stand

Little Green Pharma shares were trading at $0.065, up 6.56%, at 12:04 pm on 23 October 2026, in a session where the S&P/ASX 200 was down 0.35%. The company's most recent report, dated 31 July 2026, covered the first month of the Cannatrek merger, a cash balance of $20.6 million and a $3 million synergy target.